Immix Biopharma Inc

NASDAQ IMMX

Data sourced from

and

Download Data

Immix Biopharma Inc Income Tax Provision for the year ending December 31, 2023: USD 26.41 K

Immix Biopharma Inc Income Tax Provision is USD 26.41 K for the year ending December 31, 2023, a 157.26% change year over year. Income Tax Provision is the amount of income tax expenses recorded by a company in a given period.

Immix Biopharma Inc Income Tax Provision for the year ending December 31, 2022 was USD 10.27 K, a 70.76% change year over year.
Immix Biopharma Inc Income Tax Provision for the year ending December 31, 2021 was USD 6.01 K, a -65.73% change year over year.
Immix Biopharma Inc Income Tax Provision for the year ending December 31, 2020 was USD 17.55 K, a -14.62% change year over year.
Immix Biopharma Inc Income Tax Provision for the year ending December 31, 2019 was USD 20.55 K.

NASDAQ: IMMX

Immix Biopharma Inc

CEO	Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date	Dec. 16, 2021
Location	United States
Headquarters	11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees	14
Sector	Healthcare
Industry	Biotechnology

Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Key trends